Mibg (123i) (Iodine (123i) Iobenguane)

Iobenguane mimics norepinephrine and is taken up by cells that express the norepinephrine transporter. The attached radioactive iodine emits gamma photons, which are captured by a scintigraphic camera, producing images that reflect the distribution of sympathetic nerve tissue.

The specific dose of Mibg (123i) is determined by the prescribing physician based on the patient’s weight, clinical indication, and imaging protocol. Dosing is individualized and administered under the supervision of a qualified nuclear medicine specialist.

Safety data for Mibg (123i) in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Mibg (123i), submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Mibg (123i) is a norepinephrine analogue, offering high specificity for adrenergic tissue compared with non‑specific agents such as ¹³¹I‑MIBG. Its uptake reflects functional sympathetic activity, providing clearer delineation of pheochromocytoma and neuroblastoma lesions, while other agents may rely more on anatomical imaging.

Mibg (123i) must be stored refrigerated between 2 °C and 8 °C, protected from light, and never frozen or shaken. The vial should remain in its original packaging until use to maintain radiochemical stability.

Mibg (123i) is administered as a single intravenous injection by a qualified nuclear medicine professional. The injection is performed under aseptic conditions, and imaging typically begins a set time after administration according to the specific protocol.

Serious risks include severe allergic reactions such as anaphylaxis, sustained hypotension, cardiac arrhythmias, and radiation‑induced tissue injury at the injection site. Patients should be monitored closely during and after administration for any adverse events.

Mibg (123i) should be avoided in patients with known hypersensitivity to Iobenguane or any component of the formulation, in those where radiation exposure is contraindicated, and in pregnant or breastfeeding women unless the diagnostic benefit clearly outweighs the potential risk.